Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antibiotic Regimens for SIBO in Impoverished Children
NCT07451171Phase 2Active, not recruiting
- Sponsor
- University of Virginia
- Start
- Apr 2026
- Primary completion
- Oct 2026
- Countries
- 1
01
Overview
Phase 2, randomised trial in Small Intestinal Bacterial Overgrowth (SIBO) comparing Metronidazole, Trimethoprim-sulfamethoxazole and Metronidazole and Amoxicillin-Clavulanate (3 arms). Primary endpoint: Conversion to Glucose Hydrogen Breath Test Negativity at 15 days. Started Apr 2026; status: active, not recruiting.
02
Drugs
metronidazoletrimethoprim + sulfamethoxazoleamoxicillin + clavulanate
03
Conditions
Small Intestinal Bacterial Overgrowth (SIBO)
Beyond the preview
Go deeper on NCT07451171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07451171.